In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biokine Therapeutics Ltd.

http://biokine.com/

Latest From Biokine Therapeutics Ltd.

BioLineRx's CXCR4 Antagonist: Promising For Stem Cell Mobilization And AML

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.

Clinical Trials Cancer

Deals Shaping The Medical Industry, October 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

BioLineRx acquires Biokine's CXCR4 antagonist but switches target to leukaemia

BioLineRx has met a recent goal of adding an oncology asset to its pipeline and continued to fulfil its stated mission of filling the gap between basic research and late-stage development - especially among its Israeli colleagues - by licensing the worldwide rights to Biokine Therapeutics' BKT-140, now known as BL-8040.

Gastrointestinal Cancer

Pharmaxon SA

Pharmaxon aims to control cell mobility to fight disorders of the central nervous system and cancer. For glioblastoma, it has developed a neural cell mobility inhibitor that blocks cell migration in vitro and limits glioblastoma proliferation in animal models.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Clal Biotechnology Industries Ltd.
UsernamePublicRestriction

Register